IFIT3 overexpression
|
Cutaneous Melanoma
|
IFIT3 overexpression
|
Cutaneous Melanoma
|
dasatinib Sensitive: C3 – Early Trials
|
dasatinib Sensitive: C3 – Early Trials
|
IFIT3 overexpression
|
SCCHN
|
IFIT3 overexpression
|
SCCHN
|
gefitinib Sensitive: D – Preclinical
|
gefitinib Sensitive: D – Preclinical
|